Bio
Dr. Pape has worked in both large pharmaceutical companies and startup life science companies. At Upjohn and Parke-Davis/Warner-Lambert (now Pfizer) he was instrumental in the success of numerous cardiovascular drug discovery and development programs including Lipitor and other novel drugs. He has published 40 articles detailing the biochemistry that underlies atherosclerosis, diabetes, and obesity. Dr. Pape left Pfizer in 1998 to co-found Esperion Therapeutics, a biopharmaceutical company focused on developing novel cardiovascular therapeutics. He was involved in nearly all aspects of building Esperion, from its startup to its acquisition by Pfizer for $1.3 billion in 2004. His responsibilities as a senior executive at Esperion were numerous and varied in both the business and scientific aspects of the company. He has held research positions in the Department of Metabolic Diseases at the Upjohn Company in Kalamazoo, Michigan and in the Departments of Atherosclerosis and Molecular Biology at Parke-Davis Pharmaceutical Research (now part of Pfizer) in Ann Arbor, Michigan. Dr. Pape received his bachelor's degree in Microbiology from the University of Michigan, Ph.D. in Biochemistry from Purdue University, and MBA from the University of Chicago, Graduate School of Business. He is an Adjunct Assistant Professor in the Department of Biological Chemistry at the University of Michigan Medical School.
Career
|
Sigvion CapitalEmail: [email protected] |